Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Ben George MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
William Stapp Endowed Chair
Director, Phase 1 Clinical Trials Program
Associate Director of Cancer Genomics and Precision Medicine
Genomic Sciences and Precision Medicine Center


OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-4600

EDUCATION:
09/1992 - 08/1998 Medical College Thiruvananthapuram, Kerala, India
09/1998 - 05/1999 Research Assistant (Epidemiology), Regional Cancer Center , Thiruvananthapuram, Kerala, India, India
09/1999 - 06/2004 Doctoral Candidate, USC/Keck School of Medicine, Los Angeles, CA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
09/1998 - 05/1999 Research Assistant (Epidemiology), Regional Cancer Center, Thiruvananthapuram, Kerala, India
07/2004 - 06/2005 Internship (Internal Medicine), Medical College of Ohio, Toledo, OH
07/2005 - 06/2007 Residency (Internal Medicine), Gundersen Lutheran Medical Center, La Crosse, WI
07/2007 - 06/2010 Fellowship (Hematology/Oncology), Medical College of Wisconsin, Milwaukee, WI
07/2010 - 12/2010 Visiting Fellowship (GI Medical Oncology), The University of Texas MD Anderson Cancer Center, Houston, TX

FACULTY APPOINTMENTS:
01/2011 - 07/2016 Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, WI
07/2016 - Present Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital

ADMINISTRATIVE APPOINTMENTS:
2012 - 2013 Member of the panel involved in interviewing and selecting Residents in the Department of Internal Medicine
2012 - Present Member of the panel involved in interviewing and selecting Fellows in the Division of Hematology and Oncology
2013 - Present Institutional Co-Principal Investigator, Alliance Cooperative Group
2014 - 2017 Member of the MCW/Froedtert IRB
2015 - Present Solid Tumor Oncology Discharge Mapping Committee
2015 - Present Co-Chair, MCW Molecular Oncology Steering Committee
2015 - Present Member of the Department of Medicine ‘Task Force for Genetics in Adult Practice’ committee (Division of Hematology and Oncology representative)
2016 - Present Direct the monthly Interdisciplinary Molecular Oncology Tumor Board
07/2017 - Present Vice-Chair, Research Committee, Precision Medicine Exchange Consortium
07/2017 - Present Director, Phase 1 Clinical Trials Program, Froedtert Hospital and Medical College of Wisconsin, Clinical Cancer Center
07/2017 - Present Director, Cancer Precision Medicine Practice Integration, Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin
12/2017 - Present Pharma Task Force, Precision Medicine Exchange Consortium
06/2018 - Present Co-Chair, Cancer Precision Medicine Steering Committee, MCW
08/2019 - Present Associate Director of Cancer Genomics and Precision Medicine, Genomic Sciences and Precision Medicine Center, MCW

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
07/03/2013 - Present Institutional Co-Principal Investigator, Alliance Cooperative Group, Medicine, Hematology and Oncology, Froedtert and Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
2011 - Present St. Joseph’s Hospital, West Bend, WI
2011 - Present Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226
2011 - Present Community Memorial Hospital, Menomonee Falls, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
INTERNAL MEDICINE
2007
None
MEDICAL ONCOLOGY
2010
None
HEMATOLOGY
2010
None
 
Licensure
Number Issue DateExpiration
WISCONSIN MEDICAL LICENSE
50139-20
10/31/2021
 

AWARDS AND HONORS:
2008 - 2009 THE BEST TEACHING FELLOW IN THE DEPARTMENT OF INTERNAL MEDICINE AT MEDICAL COLLEGE OF WISCONSIN
2009 - 2010 DONALD J. SHUENKE ENDOWED CANCER FELLOWSHIP
2015 - Present selected to "Best Doctors in America"
2015 - Present Featured in the ‘Milwaukee Business Journal’ among ’Best Doctors’ in Milwaukee
2015 - Present Featured in the ‘M’ magazine among ’Best Doctors’ in Milwaukee
2017 - 2018 Annual Department of Medicine 'Murphy Award' for Excellence in Clinical Medicine, MCW
07/2019 - Present William Stapp Endowed Chair in Medicine
08/2019 - Present Froedtert and Medical College of Wisconsin Cancer Center Collaborative Award for Excellence in Clinical Research

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society of Clinical Oncology
American Association of Cancer Research
American College of Physicians

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
07/18/2013 - Present BioMed Research International
Journal Review
Clinical Cancer Research
Annals of Surgical Oncology
JNCCN
Frontiers Oncology
Journal of Cancer Research and Clinical Oncology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Molecular Analysis for Therapy Choice (MATCH)
Source:
ECOG-EAY131-MATCH
Role:
PI
Dates:
11/11/2016 - Present
 
Title:
Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Source:
ECOG-EA2142
Role:
PI
Dates:
11/14/2016 - Present
 
Title:
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Source:
NRG-GI002
Role:
Sub-Investigator
PI:
William Hall
Dates:
08/04/2017 - Present
 
Title:
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Source:
ALLIANCE-A021502-ATOMIC
Role:
Sub-Investigator
PI:
James Thomas
Dates:
08/21/2018 - Present
 
Title:
Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Source:
ALLIANCE-A021703-SOLARIS
Role:
Sub-Investigator
PI:
Sakti Chakrabarti
Dates:
02/01/2019 - Present
 
Title:
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Source:
ECOG-EA2182-DECREASE
Role:
Sub-Investigator
PI:
William Hall
Dates:
02/27/2020 - Present
 
Title:
Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Source:
NRG-GI005-COBRA
Role:
Sub-Investigator
PI:
Sakti Chakrabarti
Dates:
03/09/2020 - Present
 
Non-Peer Review
Title:
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Source:
GENENTECH-MYPATHWAY
Role:
PI
Dates:
06/28/2017 - Present
 
Title:
"An Open-label Phase I Dose Finding Trial with BI 891065 Alone and in Combination with BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Advanced and/or Metastatic Malignancies"
Source:
BI-1379-0001-REFMAL505
Role:
PI
Dates:
02/12/2018 - 03/16/2020
 
Title:
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer
Source:
IIT-TSAI-PANC
Role:
Sub-Investigator
PI:
Susan Tsai
Dates:
06/21/2018 - Present
 
Title:
"A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors"
Source:
TOLERO-TP-1287-101
Role:
PI
Dates:
12/07/2018 - Present
 
Title:
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Source:
HOFFMANN-WO39608-MORPHEUS
Role:
PI
Dates:
12/28/2018 - Present
 
Title:
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
Source:
BI-1381-REFMAL485
Role:
PI
Dates:
02/15/2019 - 03/16/2020
 
Title:
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
Source:
TORAY-950P1V02
Role:
PI
Dates:
05/19/2019 - Present
 
Title:
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination with Cytotoxic Chemotherapy in Participants with Advanced Solid Tumors
Source:
EMD-SERONO-MS201922-0001
Role:
PI
Dates:
10/21/2019 - Present
 
Title:
"A Randomized, Phase II Clinical Trial of Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma. SOFT Preop Study "
Source:
IIT-HALL-SOFT-PRE-OP
Role:
Sub-Investigator
PI:
William Hall
Dates:
10/22/2019 - Present
 
Title:
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Source:
GENENTECH-WO41535-IMBRAVE050
Role:
PI
Dates:
10/30/2019 - Present
 
Title:
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Source:
REPLIMUNE-RPL-001-16
Role:
PI
Dates:
11/07/2019 - Present
 
Title:
A Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma
Source:
JH-J1756-IRB00130075-GVAX
Role:
PI
Dates:
01/15/2020 - Present
 
Title:
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas (NAPOLI 3)
Source:
IPSEN-D-US-60010-001-NAPOLI-3
Role:
Sub-Investigator
PI:
Mandana Kamgar
Dates:
01/20/2020 - Present
 
Title:
A Phase II Trial of Nab-Paclitaxel plus Cisplatin plus Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Source:
HRI-AX-CL-PANC-PI-13301
Role:
Sub-Investigator
PI:
Mandana Kamgar
Dates:
02/05/2020 - Present
 
Title:
A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Source:
NGM-18-0402
Role:
PI
Dates:
02/20/2020 - Present
 
Title:
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
Source:
TIZONA-TTX-030-002
Role:
PI
Dates:
03/03/2020 - Present
 
Title:
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
Source:
AZ-D933GC00001-EMERALD-1
Role:
Sub-Investigator
PI:
Aditya Shreenivas
Dates:
03/04/2020 - Present
 
Title:
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Source:
MIRATI-849-002
Role:
PI
Dates:
03/16/2020 - Present
 
Title:
A Phase I Study of GNX102 in Patients with Advanced Solid Tumors
Source:
GLYCONEX-GNX-001
Role:
PI
Dates:
04/30/2020 - Present
 
Title:
Phase 2 Trial Of 5-Fluorouracil, Oxaliplatin And Liposomal Irinotecan (Plus Trastuzumab For HER2-Positive Disease) During 1st Line Treatment Of Advanced Esophageal And Gastric Adenocarcinoma
Source:
WON-UW19029
Role:
Sub-Investigator
PI:
Sakti Chakrabarti
Dates:
04/30/2020 - Present
 
Prior
Peer Review
Title:
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
Source:
ECOG-1208
Role:
PI
Dates:
07/28/2010 - 04/18/2018
 
Title:
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Source:
NSABP-P-5
Role:
Sub-Investigator
PI:
Kirk Ludwig
Dates:
06/25/2012 - 09/24/2013
 
Title:
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Source:
SWOG-S1201
Role:
PI
Dates:
11/28/2012 - 06/01/2013
 
Title:
A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)
Source:
ALLIANCE-N1048
Role:
Sub-Investigator
PI:
Kirk Ludwig
Dates:
01/22/2013 - 12/28/2019
 
Title:
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Source:
ECOG-E2211
Role:
PI
Dates:
01/20/2014 - 03/07/2016
 
Title:
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
Source:
ALLIANCE-A021202
Role:
Sub-Investigator
PI:
James Thomas
Dates:
06/23/2014 - 10/07/2016
 
Title:
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Source:
ECOG-EA2161
Role:
Sub-Investigator
PI:
James Thomas
Dates:
10/30/2017 - 01/15/2020
 
Title:
Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients with Previously Treated Hyaluronan-High (HA-high) Metastatic Pancreatic Ductal Adenocarcinoma
Source:
PCRT-16-001-PEG-PEMBRO
Role:
Sub-Investigator
PI:
Mandana Kamgar
Dates:
04/15/2019 - 11/04/2019
 
Non-Peer Review
Title:
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Source:
LILLY-14T-MC-JVBB
Role:
Sub-Investigator
PI:
James Thomas
Dates:
04/04/2011 - 03/04/2015
 
Title:
Randomized Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Non-Resectable Liver Metastases From Primary Colorectal Carcinoma
Source:
SIRFLOX
Role:
Co-Investigator
PI:
William Rilling
Dates:
06/08/2011 - 01/16/2017
 
Title:
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
Source:
HALOZYME-HALO-109-202
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
06/07/2013 - 04/07/2017
 
Title:
STEAM (Sequencing Triplet With Avastin And Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent And Sequential) Vs. Folfox/Bevacizumab In First-line Metastatic Colorectal Cancer
Source:
GENENTECH-ML28442-STEAM
Role:
Sub-Investigator
PI:
James Thomas
Dates:
02/03/2014 - 10/02/2014
 
Title:
Modular Phase II Study To Link Targeted Therapy To Patients With Pathway Activated Tumors: Module 1 - BKM120 For Patients With PI3K-Activated Tumors
Source:
NOVARTIS-SIG-BKM120
Role:
PI
Dates:
04/11/2014 - 01/29/2016
 
Title:
A Phase 1b/2 Study of OMP-59R5 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Stage IV Pancreatic Cancer ALPINE: Antibody Therapy in First-Line Pancreatic Cancer Investigating Anti-Notch Efficacy and Safety
Source:
PCRT-ONCOMED-59R5-002
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
09/02/2014 - 02/09/2017
 
Title:
Modular Phase II Study To Link Targeted Therapy To Patients With Pathway Activated Tumors: Module 8 – LEE011 For Patients With CDK4/6 Pathway Activated Tumors
Source:
NOVARTIS-SIG-LEE011
Role:
PI
Dates:
11/25/2014 - 11/03/2016
 
Title:
A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid (PNETs or GI-NETs) with Elevated Biomarkers
Source:
OXIGENE-OX4218S
Role:
Sub-Investigator
PI:
James Thomas
Dates:
02/11/2015 - 06/23/2016
 
Title:
A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Source:
CELGENE-ABI-007-ST-001
Dates:
05/11/2015 - 11/26/2018
 
Title:
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)
Source:
INCYTE-INCB-18424-362
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
09/04/2015 - 10/17/2016
 
Title:
A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Flourouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Source:
MERCK-MK-3475-059
Role:
PI
Dates:
09/30/2015 - 03/06/2020
 
Title:
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
Source:
MERCK-MK-3475-061
Role:
PI
Dates:
12/11/2015 - 06/13/2018
 
Title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
Source:
ASTELLAS-9785-CL-3021
Role:
PI
Dates:
07/01/2016 - 03/07/2018
 
Title:
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Source:
MERCK-MK-3475-062
Role:
PI
Dates:
07/11/2016 - 04/28/2017
 
Title:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-high Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Source:
HALOZYME-HALO-109-301
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
07/12/2016 - 12/16/2019
 
Title:
Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) versus Placebo Plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments
Source:
TAIHO-TO-TAS-102-302
Role:
PI
Dates:
08/19/2016 - 08/21/2018
 
Title:
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously with or without Gemcitabine as 2nd/3rd Line Therapy in Advanced Pancreatic Cancer Patients
Source:
BERG-15-002-PCRT
Role:
Sub-Investigator
PI:
Mandana Kamgar
Dates:
11/14/2016 - 03/01/2019
 
Title:
Efficacy of Doxycycline on Metakaryote Cell Death in Patients with Resectable Pancreatic Cancer
Source:
IIT-TSAI-METAKARYOC-REV2
Role:
Sub-Investigator
PI:
Susan Tsai
Dates:
04/03/2017 - 07/06/2018
 
Title:
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy
Source:
INCYTE-INCB-54828-202
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
07/25/2017 - 04/12/2019
 
Title:
An Open-Label, Multicenter Phase Ib Study of the Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Bevacizumab and/or Other Treatments in Patients with Solid Tumors
Source:
HOFFMANN-LAROCHE-GO30140
Role:
PI
Dates:
08/07/2017 - 07/22/2019
 
Title:
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Source:
ARMO-AM0010-301-SEQUOIA-LILLY
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
08/29/2017 - 12/13/2019
 
Title:
"A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Cisplatin Plus Gemcitabine and PEGPH20 in Combination with Atezolizumab and Cisplatin Plus Gemcitabine Compared with Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma "
Source:
HALOZYME-HALO-110-101
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
11/15/2017 - 01/09/2020
 
Title:
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab with Nivolumab in Unresectable Hepatocellular Carcinoma
Source:
UC-17-0578-HCC
Role:
PI
Dates:
04/26/2018 - 03/13/2019
 
Title:
Phase 1/2 Study Of TAS-120 In Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Source:
TAIHO-TPU-TAS-120-101
Role:
PI
Dates:
07/31/2018 - 11/30/2019
 
Title:
Tate Versus Tace, an Open-Label Randomized Study Comparing Transarterial Tirapazamine Embolization versus Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma
Source:
TECLISON-LT006-TATEVSTACE
Role:
Sub-Investigator
PI:
William Rilling
Dates:
05/09/2019 - 08/30/2019
 
Title:
"A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)"
Source:
TGEN-17-001-SU2C-CATALYST
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
08/09/2019 - 12/26/2019
 
Title:
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination with Abraxane® in Subjects with Metastatic Pancreatic Cancer
Source:
REXAHN-RX3117-003
Role:
Sub-Investigator
PI:
Paul Ritch
Dates:
10/08/2019 - 01/03/2020
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Choosing a career in Medical Oncology, Lecture for the Medical Students, Medical College of WI, 11/16/2011
Annual Didactic Lecture for Internal Medicine Residents on Colorectal Cancer, Medical College of Wisconsin, 2011 - Present
Annual Didactic Lecture for Hematology/Oncology Fellows on Gastro-Esophageal Malignancies, Medical College of Wisconsin, 2011 - Present
Chemotherapy for Pancreatic Cancer, HPB Didactic Lecture, Medical College of WI, 03/01/2012
Initial Experience with FOLFIRINOX in the neo-adjuvant setting for patients with Borderline Resectable Pancreatic Cancer, Division of Hematology and Oncology Research Meeting, Medical College of WI, 11/15/2012
Chemotherapy for Pancreatic Cancer – Past, Present and Future’.‘Novel Treatment Sequencing, Pancreatic Cancer Symposium, Milwaukee Art Museum, Milwaukee, WI, 02/16/2013
Multimodality Treatment of Foregut Malignancies – Timing is Everything’, GI ASCO update, Medical College of Wisconsin Alumni Center, 03/23/2013
Clinicopathologic Conference for the Internal Medicine Residents, Medical College of WI, 11/2013
Integration of Locoregional Therapy with Systemic Therapy in patients with metastatic Colorectal Cancer, HPB Didactic Lecture Series, Medical College of WI, 04/03/2014
Locally Advanced Pancreatic Cancer, HPB Didactic Lecture Series, MCW, 04/03/2014
Clinical Trials in the Pancreatic Cancer Program, Annual Cancer Center Scientific Retreat, Serb Hall, Milwaukee, 06/06/2014
Chemotherapy in the management of Pancreatic Cancer, Community Memorial Hospital, Menomonee Falls, WI, 08/29/2014 - 08/29/2017
Challenges in delivering FOLFIRINOX and Gemcitabine-Nab Paclitaxel, The Annual Pancreatic Cancer Symposium, Milwaukee Art Museum, Milwaukee, WI, 09/05/2014
Pancreatic Cancer – Treatment Approaches, Pancreatic Cancer Action Network (PanCAN), Radisson Hotel, Milwaukee, WI, 10/01/2014
Role of Molecular Profiling in patients with metastatic Colorectal Cancer, The Symposium on Metastatic Colon Cancer, Milwaukee, WI, 05/01/2015
Molecular Classification of Pancreatic Cancer, HPB Didactic Lecture, Medical College of WI, 06/02/2016
Role of Molecular Markers and the Newest Tumor Board, Regional Therapies Symposium, Milwaukee, WI, 08/04/2016
Neuroendocrine Cancer -Subtypes, Natural History and Treatment, Didactic Lecture for the Interventional Radiology Fellows, Medical College of WI, 12/01/2016
GI ASCO Update 2017, Pancreatic Cancer Symposium, Milwaukee, WI, 01/27/2017
Treatment Sequencing in Localized Pancreas cancer, Pathology Grand Rounds, Froedtert and Medical College of Wisconsin, 10/12/2018
Treatment Sequencing in Localized Pancreas cancer, Transplant Surgery Grand Rounds, Froedtert and Medical College of Wisconsin, 12/04/2018
 
Regional
Treatment Sequencing for Gastric Cancer: Is there an ideal approach?, Invited Lecture at St. Agnes Hospital, Fon Du Lac, WI, 02/13/2014
Modern Metastatic Colorectal Cancer Management, Fox Valley Hematology/Oncology Group, Appleton, WI, 11/06/2014
Multi-modality Therapy for Management of Gastro-Esophageal malignancies: Optimal Treatment Sequencing, Invited lecture at St. Vincent Hospital, Green Bay, WI, 09/11/2015
Molecular profiling in GI Cancers, Invited lecture at the Spotlight on Peritoneal surface malignancies Conference, Kohler, WI, 08/04/2017
Treatment Sequencing in Localized Pancreas cancer, Aspirus Spring Oncology Forum, Wausau, WI, 04/27/2019
Pancreatic Ductal Adenocarcinoma – A Review of the Treatment Landscape, Pancreatic Cancer Translational Science Symposium, Milwaukee, WI, 10/25/2019
Updates in Colorectal Cancer, Annual Advances in Hematology and Oncology Symposium, Green Bay, WI, 10/26/2019
ASCO GI Updates, Milwaukee, WI, 01/31/2020
 
National
Sequencing Chemotherapy and Radioembolization in the treatment of metastatic Colorectal Cancer, Invited lecture for the Florida Interventional Specialists, Tampa, FL, 05/29/2014
Modern Metastatic Colorectal Cancer Management, Florida Fish Memorial Hospital, Orange City, Florida, 07/11/2014
Modern Metastatic Colorectal Cancer Management, Lankenau Hospital, Wynnewood, Pennsylvania, 10/13/2014
The Case for Integration of Locoregional Therapy with Systemic Therapy in metastatic Colorectal Cancer, Invited lecture at the Annual World Congress of Interventional Oncology (WCIO), New York, 05/06/2015 - 05/09/2016
The Case for Integration of Loco-regional Therapy with Systemic Therapy for Colorectal Liver Metastases, Invited Lecture at the Annual World Congress of Interventional Oncology (WCIO) metastatic Colorectal Cancer Plenary Session, Boston, MA, 06/09/2016 - 06/12/2016
NCCN Updates- Medical Oncology Perspective’, Invited Lecture at the Society of Interventional Radiology Annual Meeting, Washington DC, 03/05/2017 - Present
Combining Intra-arterial Therapy with Chemotherapy for mCRC, Invited Lecture at the Society of Interventional Radiology Annual Meeting, Washington DC, 03/07/2017
Invited Panelist for the metastatic Colorectal Cancer Tumor Board, The World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
Moderated the metastatic Colorectal Cancer session, the World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
When Should IO Therapy Be Integrated into Systemic Therapy?, Invited lecture at the World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
Y90 by lines of therapy: Can we justify administration of Y90 on earlier chemotherapy lines? NO: only on Trial, Society of Interventional Radiology Annual Meeting, Los Angeles, California, 03/19/2018
Treatment Sequencing in Localized Pancreas Cancer, Cancer Center Grand Rounds, University of Nebraska, Omaha, Nebraska, 01/21/2019
A Primer: Systemic Therapies in the Era of Molecular Subtyping, plenary session on Colorectal Liver Metastases at the Annual Society of Interventional Oncology Meeting, Boston, MA, 06/09/2019
What is Oligometastatic Disease.Plenary session on Lung Mets Comparative Effectiveness, Annual Society of Interventional Oncology Meeting, Boston, MA, 06/10/2019
 
International
Adjuvant and Neo-adjuvant Strategies for Colorectal Cancer, Invited Lecture at the Colorectal Continuing Medical Education Symposium, Thruvananthapuram, Kerala, India, 11/07/2015 - 11/08/2015
Limits of Systemic Therapies - Individualized Local Approaches, Invited Lecture at the European Conference on Interventional Oncology (ECIO), Dublin, Ireland, 04/17/2016 - 04/20/2016
Management of Metastatic Colorectal Cancer, Saint Paul Millennium Medical College, University of Addis Ababa, Addis Ababa, Ethiopia, 11/27/2017
Treatment Sequencing in Localized Gastro-Esophageal Cancer, Invited Lecture at Saint Paul Millennium Medical College, University o Addis Ababa, Addis Ababa, Ethiopia, 11/28/2017
Management of Metastatic Gastro-Esophageal Cancer, Invited Lecture at Saint Paul Millennium Medical College, University o Addis Ababa, Addis Ababa, Ethiopia, 12/01/2017
Treatment Sequencing in Localized Pancreas Cancer, Kochi Oncology Group Meeting, Kochi, Kerala, India, 08/11/2018
 

COMMUNITY SERVICE ACTIVITIES:
Ellen’s Icebreaker fund for gastric Cancer: Fundraising activity by a grateful patient’s family. They have raised approximately $ 70,000 over the last 2 years
Sebastian Raclaw Abdominal Cancer Research Fund: Fundraising activity (`$25,000) by a grateful patient’s family (dedicated to Dr. Turaga and me)
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. George B, Cote RJ, Datar RH; Nucleic Acids in Prognosis, National Medical Journal of India 14(3): 163-7, 2001
2. Chatterjee SJ, Datar RH, Youssefzadeh D, George B, Stein JP, Young L, Shi S-R, Gee C, Groshen SG, Skinner DG, Cote RJ; The combined effects of p53,p21 and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology 22 (6):1007-1013, 2004
3. Pagliarulo V, George B, Beil SJ, Groshen SG, Laird PW, Cai J, Willey JC, Cote RJ, Datar RH; Sensitivity and reproducibility of standardized competitive RT PCR for transcript quantification and its comparison with real-time RT-PCR. Molecular Cancer 3: 5-11, 2004
4. Chatterjee SJ, George B, Shi S-R, Datar RH, Goebell PJ, Fung YK, Jones PA, Cordon-Cardo C, Cote RJ; Hyperphosphorylation of pRB: a mechanism for Rb tumor suppressor pathway inactivation in bladder cancer. Journal of Pathology 203: 762-770, 2004
5. George B, Cote RJ, Datar RH; Does the decatenation G2 checkpoint suppress bladder carcinogenesis (Commentary). American Journal of Urology Review 2(7):347-350, 2004
6. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP;The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6:159, 2006
7. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ,Groshen S, Stein J, Skinner D, Jones PA, Cote RJ;p53 Gene and Protein Status:The role of p53 Alterations in Predicting Outcome in Patients with Bladder Cancer. Journal of Clinical Oncology 25 (34):5352-5358, 2007
8. George B, Wirostko WJ, Connor TB, Choong NW. Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol. 2009 May;4(5):661-2.
9. Sukumaran S, George B, Parameshwaran NH, Drobyski WR; Posterior Reversible Encephalopathy Syndrome (PRES) in association with high dose steroids after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 45: 779-780, 2010
10. Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. Bone Marrow Transplantation. 2011 Apr 11. [Epub ahead of print]
11. George B, Kopetz S; Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports 13(3):206-15, 2011
12. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C.Survival Benefit Associated with Surgical Oophorectomy in Patients with Colorectal Cancer Metastatic to the Ovary. Clinical Colorectal Cancer. 11 (3): 191-194, 2012
13. Wilson JM, Groeschl R, George B, Turaga KK, Patel PJ, Saeian K, Gamblin TC. Ciliated hepatic cyst leading to squamous cell carcinoma of the liver - A case report and review of the literature. Int J Surg Case Rep. 2013;4(11):972-5. PMCID: PMC3825928
14. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014 Jan;21(1):240-7.
15. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar;19(3):266-74. PMCID: PMC3958454
16. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas SG, Gamblin, TC, Turaga KK. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surg Endosc - 2014 Apr 02
17. Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur. J. Cancer – 2014 Apr 29
18. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B ,Tolat P, Evans DB. Arterial resection at the time of pancreatectomy for cancer. Surgery, 2014, May 03
19. Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC. Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014 May 21
20. Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiotherapy and Oncology. 2014 October;113 (1):41- 6
21. Krepline AN, Christians KK, Duelge K, Mahmoud A, Ritch P, George B, Erickson BA, Foley WD, Quebbeman EJ, Turaga KK, Johnston FM, Gamblin TC, Evans DB, Tsai S. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. Journal of Gastrointestinal Surgery. November 2014 (11) 2016-2025
22. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. HPB (Oxford). 2015 Feb;17(2):131-9
23. Humphrey SR, Hussain A, Chandran R, Wilson B, George B. An acute onset of acrokeratosis paraneoplastica. JAMA Dermatology, 2015 March 11.
24. Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor Profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy 2015 March 16:1-6
25. Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Mar 17
26. Epperla N, George, B. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer, May 2015 (Epub)
27. Evans DB, George B, Tsai S. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced – definitions of increasing importance for the optimal delivery of multimodality therapy. Invited editorial for Annals of Surgical Oncology, June 2015 (Epub)
28. Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015 Aug;6(4):418-29
29. Aldakkak M, Christians K, Krepline AN, George B, Ritch P, Erickson B, Johnston F; Evans DB, Tsai S. Pre-treatment CA 19-9 Does Not Predict the Response to Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer. HPB (Oxford). August 2015
30. Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. August 2015
31. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS One. 2015 Oct 8;10(10)
32. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 patients.Clinical Colorectal Cancer.2015 Dec 29 (Epub)
33. Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract. 2016 Oct;12(10):915-923.
34. Christians KK, Hemler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016. Oct 23 (Epub)
35. Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? J Surg Oncol. 2016 Oct;114(5):581-586.
36. Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. J Gastrointest Surg. 2017 Mar;21(3):496-505
37. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16;171(5):1042-1056.e10
38. Blitzer GC, Hall WA, Tsai S, Aldakkak M, Hellman RS, Evans DB, Christians KK, George B, Ritch PS, Erickson BA. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Pract Radiat Oncol. 2017 Nov - Dec;7(6):e449-e45
39. Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017 Nov;21(11):1793-1803.
40. Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 10;268(4):610-619.
41. Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK. Locally advanced pancreas cancer: Staging and goals of therapy. Surgery. 2018 Jan 10. pii: S0039-6060(17)30633-5.(Epub ahead of print)
42. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 levels following Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer. Ann Surg. 2018 Oct 11. doi: 10.1097/SLA.0000000000003049. [Epub ahead of print]
43. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. iScience. 2018 Nov 30;9:258-277
44. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 Jan 4: [Epub ahead of print].
45. Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019 Jan 24;7(1):18.
46. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 Feb 1;7(1):27
47. Singhi AD, *George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 Mar 2. [Epub ahead of print] * Equal Contribution
48. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hing JC.Downstaging Locally-Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. Journal of Surgical Research. Accepted for publication April 2019.
49. Singavi A, Ramalingam V, George, B. Etanercept for Treatment of Taxane-Induced Pneumonitis. Journal of Oncology Practice. June 20, 2019.
50. Ilson DH, Tabernero J, Prokharau A, Arkenau H, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta, GD. Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil in patients with metastatic gastric Cancer and prior gastrectomy: subgroup analyses of the a randomized phase 3 trial (TAGS). JAMA Oncology. June 2019. Accepted for publication.
51. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.Surgery. 2019 Sep;166(3):277-285
52. Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02;25(2):362-368. PMCID: PMC6339825
53. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore P, Banerjee S, Lyons L, Louis CU, Jin Ong T, Kelly K. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019; 9: 1256
54. Wong M, Kim J, George B, Erikson C, Pearson T, Robbins J, Zimmermann MA, Hong JC, Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. J Surg Res. 2019 Oct, 242:23-30.
55. Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg. 2020 Feb;24(2):235-242. doi: 10.1007/s11605-019-04423-6. Epub 2019 Nov 19
56. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020 04;271(4):740-747.
57. Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol. 2020 Apr 15;10:460. doi: 10.3389/fonc.2020.00460. eCollection 2020
58. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020 Apr 17;10:500. doi: 10.3389/fonc.2020.00500. eCollection 2020
59. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford). 2020 Apr 27. pii: S1365-182X(20)30109-X. doi: 10.1016/j.hpb.2020.03.022. [Epub ahead of print]
60. Wainberg Z, Hochster H, Kim E, George B, Kaylan A, Cjhiorean E.B, Waterhouse D, Guiterrez M, Parikh A, Jain R, Carrizosa S, Soliman H, Lila T, Reiss D, Pierce S, Bhore R, Banerjee S, Lyons L, Louis C, Jin Ong T, O'Dwyer P. Open-Label, Phase 1 Study of Nivolumab Combined With nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clinical Cancer Research, Manuscript Number: CCR-20-0099R1
61. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 09 15;26(18):4814-4822.
62. Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, Shaw BE, Satwani P. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020 05 12;4(9):2084-2094. PMCID: PMC7218429
63. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020;10:500. PMCID: PMC7180175
64. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford). 2020 12;22(12):1745-1752.
65. Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol. 2020;10:460. PMCID: PMC7175033
66. Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06;26(6):1137-1143. PMCID: PMC7367282
67. Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg. 2020 02;24(2):235-242.
68. Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Dec;26(13):4515-4521.
69. Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 01;6(1):e193531. PMCID: PMC6802061
70. Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Ann Surg Oncol. 2020 Jan;27(1):85-97.
71. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019 09;166(3):277-285.
72. Singavi AK, Ramalingam V, George B. Etanercept for Treatment of Taxane-Induced Pneumonitis. J Oncol Pract. 2019 10;15(10):556-557.
73. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. J Surg Res. 2019 10;242:23-30.
74. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06;156(8):2242-2253.e4.
75. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 02 01;7(1):27. PMCID: PMC6359802
76. Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019 01 24;7(1):18. PMCID: PMC6346512
77. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. iScience. 2018 Nov 30;9:258-277. PMCID: PMC6234258
78. Chung J, Maruvka YE, Sudhaman S, Kelly J, Haradhvala NJ, Bianchi V, Edwards M, Forster VJ, Nunes NM, Galati MA, Komosa M, Deshmukh S, Cabric V, Davidson S, Zatzman M, Light N, Hayes R, Brunga L, Anderson ND, Ho B, Hodel KP, Siddaway R, Morrissy AS, Bowers DC, Larouche V, Bronsema A, Osborn M, Cole KA, Opocher E, Mason G, Thomas GA, George B, Ziegler DS, Lindhorst S, Vanan M, Yalon-Oren M, Reddy AT, Massimino M, Tomboc P, Van Damme A, Lossos A, Durno C, Aronson M, Morgenstern DA, Bouffet E, Huang A, Taylor MD, Villani A, Malkin D, Hawkins CE, Pursell ZF, Shlien A, Kunkel TA, Getz G, Tabori U. DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discov. 2021 05;11(5):1176-1191. PMCID: PMC8223607
79. Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Am J Surg. 2021 07;222(1):10-17.
80. Bona K, Brazauskas R, He N, Lehmann L, Abdel-Azim H, Ahmed IA, Al-Homsi AS, Aljurf M, Arnold SD, Badawy SM, Battiwalla M, Beattie S, Bhatt NS, Dalal J, Dandoy CE, Diaz MA, Frangoul HA, Freytes CO, Ganguly S, George B, Gomez-Almaguer D, Hahn T, Kamble RT, Knight JM, LeMaistre CF, Law J, Lazarus HM, Majhail NS, Olsson RF, Preussler J, Savani BN, Schears R, Seo S, Sharma A, Srivastava A, Steinberg A, Szwajcer D, Wirk B, Yoshimi A, Khera N, Wood WA, Hashmi S, Duncan CN, Saber W. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood. 2021 01 28;137(4):556-568. PMCID: PMC7845011
81. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70. PMCID: PMC7543702
82. Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01;27(1):68.e1-68.e9. PMCID: PMC8015679
83. Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol. 2021 Apr;28(4):2246-2256.
84. Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery. 2021 03;169(3):629-635.
85. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery. 2020 09;168(3):440-447.
86. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019;9:1256. PMCID: PMC6901975
87. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 02 20;37(6):461-470.
88. Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biol Ther. 2015;16(5):764-9. PMCID: PMC4622996
 
Books, Chapters, and Reviews
1. George B, Datar RH, Cote RJ; Molecular biology of bladder cancer : Cell Cycle Alterations. Chapter 10 (pages 107-122), Textbook of Bladder Cancer, Taylor & Francis Ltd, 2006
2. Tsai S, George B, Christians KK, Evans DB. Neoadjuvant chemotherapy and radiochemotherapy: is there a survival advantage for pancreatic cancer patients. In Beger HG, Nakao A, Neoptolemos JP, Peng SY, Sarr MG, eds. Pancreatic Cancer, Cystic Neoplasms, and Endocrine Tumors: Diagnosis and Management. Oxford: Wiley-Blackwell, 2015.
3. American Cancer Society Book Chapter on Rectal Cancer (with Kosinski, Turaga and Johnstone) 2017(in press)
4. Delivery of Neoadjuvant versus Adjuvant Therapy in Localized Pancreatic Cancer. George B and Ritch PS. ’Management of Localized Pancreatic Cancer’ Springer Nature. (In preparation).
5. Use of Molecular Profiling in Localized PC. George B. ’Management of Localized Pancreatic Cancer’ Springer Nature. (In preparation).
 
Abstracts
1. Goebell PJ, George B, Brands FH, Datar RH, Shi S-R, Stein JP, Cote RJ: p21WAF/Cip1, p27Kip1 and p53 expression in bladder cancer (Seminar). 18th Annual Meeting of the Urological Research Society, Izmir, Turkey, September13-15, 2001
2. George B, Goebell PJ, Datar RH, Cai J, Brands FH, Young LL, Shi S-R, Groshen SG, Stein JP, Skinner DG, Cote RJ: p21Waf/Cip1, p27Kip1and p53; expression and impact on clinical outcome in invasive bladder cancer (Seminar). 38th Annual Meeting of the American Society Of Clinical Oncology, Orlando, Florida, May18-21, 2002
3. George B, Datar RH, Wu L, Beil SJ, Patten N, Cai J, Groshen SG, Cote RJ: Functional Role of p53 in invasive bladder cancer: A correlation between gene status by GeneChip analysis and protein expression by Immunohistochemistry (Poster). Affymetrix User Group Meeting, SanDiego May 6-7, 2003
4. Pagliarulo V, George B, Groshen SG, Laird PW, Cai J, Willey J, Datar RH, Cote RJ; Sensitivity and reproducibility of standardized competitive RT PCR for transcript Quantification and its comparison with real-time RT-PCR (poster). 94th Annual Meeting of the American Association for Cancer Research, Washington DC, July 11-14, 2003
5. George B, Pagliarulo V, Beil SJ, Buckley J, Datar RH, Cote RJ; Molecular Characterization of Bladder cancer cell lines by quantitative transcript profiling using the StaRT PCR assay (poster). 94th Annual Meeting of the American Association for Cancer Research, Washington DC, July 11-14, 2003
6. George B, Datar RH, Wu L, Beil SJ, Patten N, Cai J, Groshen SG, Cote RJ: Complete p53 Multi- exon Sequencing by GeneChip Complements Use of p53 Immunohistochemistry for Prediction of Clinical Outcome in Invasive Bladder Cancer (poster). 95th Annual Meeting of the American Association for Cancer Research, Orlando, Florida, March27-31, 2004
7. Beil SJ, George B, Wu L, Cai J, Patten N, Young L, Groshen SG, Datar RH, Cote RJ; Comparison of p53 genotype and phenotype:Site of mutation predicts outcome in patients with bladder cancer. American Society of Clinical Oncology. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9561
8. Oettel KR, Joseph R, George B, Lee JA, Mathiason MA, Meyer L, Go RS; Compliance to National Comprehensive Cancer Network guidelines in patients with newly diagnosed small cell lung cancer at a community cancer center. American Society of Clinical Oncology. Vol 25, No. 18S (June 20 Supplement), 2007: 17064
9. George B, Simhan S, Lee JA, Mathiason MA, Go RS; Conflicts of interest among articles published in the Journal of Clinical Oncology. American Society of Clinical Oncology. Vol 25, No. 18S (June 20 Supplement), 2007: 6633
10. Olteanu H, Harrington A, George B, Bredeson C, Parameshwaran NH, Kroft S; High Prevalence of Dapsone Induced Oxidant Hemolysis in North American Stem cell Transplant Recipients with Glucose-6-Phosphate Dehydrogenase Deficiency. American Society of Hematology (Blood) November 2009; 114:3314
11. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29: 2011 (suppl; abstr 3618)
12. George B, You N, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR; Survival Advantage Associated with Palliative Oophorectomy in Patients with Metastatic Colorectal Cancer to the Ovaries: A Single Institution Retrospective Analysis. Abstract ID 539, Gastrointestinal Cancers Symposium, San Francisco, California, January 20- 22, 2011
13. George B, You N, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR; Palliative Oophorectomy in Patients with Metastatic Colorectal Cancer to the Ovaries. Poster ID P156, Society of Surgical Oncology Annual Cancer Symposium, San Antonio, Texas March 2-5, 2011
14. George B, Estrella J, Machado,KK Ferrarotto R, Hoff PM, Rashid A, Kopetz, S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis. J Clin Oncol 29: 2011 (suppl; abstr e14040)
15. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29: 2011 (suppl 4; abstr 507)
16. Kharofa JR, Kelly T, Wood C, George B, Tsai S, Ritch P, Wiebe L, Christians K, Evans D, Erickson B. Neoadjuvant Chemoradiation with IMRT in Resectable and Borderline Resectable Pancreatic Cancer (PCa). ASTRO 2012
17. Kharofa J, Kelly T, Ritch P, George B, Wiebe LA, Thomas JP, Christians K, Evans DB, Erickson B. 5-FUleucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic Cancer 2012 GI ASCO
18. Kharofa J, Kelly TR , Ritch PS, George B, Wiebe LA, Thomas JP, Christians KK, Evans DB, Erickson B. 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol 30, 2012 (suppl; abstr e14613).
19. Kharofa J, Kelly T, Wood C, George B, Tsai S, Ritch P, Wiebe L, Christians K, Evans D, Erickson B. Local control in Resectable and Borderline Resectable Pancreatic Cancer Treated with Preoperative Chemoradiation Using IMRT or Chemotherapy Alone. 2013 ASCO-ASTRO 2013 January 24-26, 2013
20. Christians K, Tsai S, Mahmoud A, Ritch P, Thomas J, Wiebe L, Kelly T, Erickson B, Wang H, Evans D, George B. Neoadjuvant FOLFIRINOX For Borderline Resectable Pancreas Cancer - A New Treatment Paradigm? Association of VA Surgeons Meeting, Milwaukee, April 21, 2013
21. George B, Ritch PS, Thomas JP, Wiebe LA, Mahmoud A, Christians KK, Pappas SG, Turaga KK, Quebbeman EJ, Gamblin TC, Erickson B, Kelly TR, Evans DB, Tsai S. Utility of pretreatment serum carcinoembryonic antigen (CEA) level in patients with localized pancreatic cancer (LPCa). Pancreas Club 2013
22. Miura JT, Krepline A, Duelge KD, George B, Ritch PS, Erickson B, Thomas JP, Mahmoud A, Quebbeman EJ, Turaga KK, Johnston FM, Christians KK, Gamblin TC, Evans DB, Tsai S. Neoadjuvant therapy for pancreatic cancer in patients older than age 75. GI ASCO 2014
23. Longo JM, Siker ML, George B, Kosinski L, Ludwig KA, Otterson M, Thomas JP, Wiebe LA, Erickson B. Helical tomotherapy with concurrent chemotherapy in the treatment of anal canal carcinoma: A review of clinical outcomes at a tertiary referral center. GI ASCO 2014
24. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high-grade neuroendocrine carcinoma: A single institution experience. GI ASCO 2014
25. Krepline, AN, Aldakkak, M, George, B, Ritch, PS, Erickson, BA, Johnston, F, Christians, KK, Evans, DB, Tsai, S. Importance of Preoperative CA 19-9 Levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. Society of Surgical Oncology, 2014
26. Aldakkak, M, Christians, KK, Krepline, AN, George, B, Ritch, PS, Erickson, BA, Johnston, F, Evans, DB, Tsai, S. Pretreatment Serum CA 19-9 Levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. Society of Surgical Oncology, 2014
27. Giever T, Ritch P, Thomas J, Wiebe L, Haasler G, Gasparri M, Johnstone D, Johnstone C, Gore E, George B. A combination of Cisplatin, Irinotecan, and Paclitaxel (CIP) as frontline treatment of patients with metastatic Esophageal Cancer (mEC) AACR 2014
28. Tsai S, Christians KK, Dua K, Khan A, Oh Y, George B, Ritch P, Erickson BA, Hunt B, Rao A, Mackinnon AC, Evans DE. Rapid immunohistochemical analysis of pancreatic cancer cytology from endoscopic ultrasound guided fine needle aspirates. 2014 AACR Meeting, New Orleans
29. Amini, A, Krepline, AN, Mahmoud, A, George, B, Ritch, PS, Erickson, BA, Thomas, JP, Quebbeman, EJ, Turaga, KK, Johnston, F, Gamblin, TC, Christians, KK, Evans, DB, Tsai, S. Feasibility of Resection after Induction Therapy for Locally Advanced Pancreatic Cancer. Poster Presentation 2014 SSO Meeting, Phoenix, AZ
30. Miura, J, Krepline, AN, Deluge, J, George, B, Ritch, PS, Erickson, BA, Thomas, JP, Mahmoud, A, Quebbeman, EJ, Turaga, KK, Johnston, F, Christians, KK, Gamblin, TC, Evans, DB, Tsai, S. Neoadjuvant Therapy for Pancreatic Cancer in Patients > age 75. Poster Presentation 2014 SSO Meeting, Phoenix, AZ
31. Heimler, JW, Krepline, AN, George, B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai, S. Survival Outcomes of Patients with Resectable Pancreatic Cancer Receiving Neoadjuvant Therapy. WI Surgical Meeting 2014
32. Krepline, AN, George, B, Ritch, PS, Erickson, BA, Thomas, JP, Mahmoud, A, Quebbeman, EJ, Turaga, KK, Johnston, F, Gamblin, TC, Christians, KK, Evans, DB, Tsai, S. Prophylactic anticoagulation for superior mesenteric vein or portal vein narrowing/occlusion in borderline resectable pancreatic adenocarcinoma patients. Poster Presentation 2014 AHPBA Meeting, Miami, FL
33. Krepline, AN, Aldakkak M, George, B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai, S. Importance of Preoperative CA19-9 levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. SSO 2015 Houston. Oral Presentation
34. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson EA, Johnston FM, Evans DB, Tsai S. Pre-treatment CA19-9 does not predict the response to Neoadjuvant therapy in patients with Localized Pancreatic Cancer March 2015 AHPBA Miami, FL
35. Miura TJ, Johnston FM, Tsai S, George B, Thomas JP, Christians KK, Turaga K, Pawlik TM, Ga,blin C. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy. GI ASCO, 2015
36. Giever T, Ranade A, Thomas JP, Ritch P, Wiebe L, Haasler G, Gasparri M, Johnstone D, Gore E, Johnstone C, Dua K, Khan A, Oh Y, George B. Utility of invasive staging procedures in patients (pts) with localized esophageal cancer. GI ASCO, 2015
37. Miura, J, Aldakkak, MA, Krepline, AN, George, B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai S. Gender-based Differences in Survival Among Patients with Localized Pancreatic Cancer. Soc Black Acad Surg 2015, Chapel Hill, NC. Oral Presentation
38. D Waterhouse, M Gutierrez, T Bekaii-Saab, W DeRosa, Z Wainberg, B George, C Duval Fraser, A Ko, DW Pierce, S Stergiopoulos, H Soliman Nab-paclitaxel (nab-P) plus nivolumab (Nivo) in human epidermal growth factor receptor 2 (HER2)–negative recurrent metastatic breast cancer (MBC). CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015, San Antonio, TX
39. Tsai S, Ritch PS, Erickson B, George B, Johnston FM, Mackinnon AC, Evans DB, Christians KK. Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial. GI ASCO, 2016
40. Chrabaszcz S, Rajeev R, Klooster B, Chinn A, Gamblin TC, Johnston FM, George, B, Banerjee A, Turaga K. Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials. GI ASCO, 2016
41. Firdaus I, Waterhouse DM, Gitierrez, M, Wainberg, ZA, George B, Kelly K, Bekaii-Saab TS, Carrizosa DR, Soliman HH, Fraser CD, Ko A, Pierce DW, Manax VG, Stergiopoulos, SG, Hochster, HH. nab-paclitaxel (nab-P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). GI ASCO, 2016
42. Schmidt S, Pattali S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Can the sequence of chemotherapy regimens influence outcome in patients with Metastatic Pancreatic Adenocarcinoma (MPAC)? GI ASCO 2016
43. Pattali S, Schmidt S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Can Response to treatment predict outcome in patients with Metastatic Pancreatic Adenocarcinoma (MPAC)? GI ASCO 2016 (Merit Award)
44. Schmidt S, Pattali S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and Gemcitabine + nab-paclitaxel (NabG). GI ASCO 2016
45. Barnes, CA, Aldakkak, M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Tolat P, Foley WD, Evans DB,Tsai, S. Impact of Treatment Sequencing on Sites of First Recurrence in Patients with Localized Pancreatic Cancer. SSAT 2016, San Diego, CA
46. Barnes CA, Aldakkak M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Hagan C, Oshima K, Evans DB, Tsai S. Impact of Number of Regional Lymph Node Metastasis in Patient with Localized Pancreatic Cancer Following Neoadjvuant Therapy. April 2016. Assoc of VA Surgeons. Virginia Beach, VA
47. D Waterhouse, B George, M Gutierrez, G Otterson, A Ko, TJ Ong, N Trunova, K Kelly. Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Safety and Efficacy Results. AACR Special Conference on Pancreatic Cancer. May 12-15, 2016, Orlando, FL.
48. Barnes, CA, Aldakkak, M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Tolat P, Foley WD, Evans DB, Tsai, S. Impact of Treatment Sequencing on Sites of First Recurrence in Patients with Localized Pancreatic Cancer. May 2016 Pancreas Club. San Diego, CA
49. Pattali S, Sreenivasan J, Premnath N, Schmidt S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Retrospective review of efficacy and dose intensity of second-line (SL) Nab-paclitaxel plus gemcitabine (NabG) for patients with metastatic pancreatic adenocarcinoma (MPAC) after first-line (FL) FOLFIRINOX (FFX). Pancreas Club Annual Meeting, May 20-21, 2016, San Diego, CA
50. Barnes CA, Aldakkak M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Hagan C, Oshima K, Evans DB, Tsai S. Impact of Number of Regional Lymph Node Metastasis in Patient with Localized Pancreatic Cancer Following Neoadjvuant Therapy. May 2016 Pancreas Club, San Diego, CA
51. Paul Rajamanickam ES, Christians KK, Krepline AN, Aldakkak M, George B, Ritch PS, Erickson BA, Evans, DB, Tsai S. Poor Glycemic Control is Associated with Failure to Complete Neoadjvuant Therapy and Surgery in Patients with Localized Pancreatic Cancer. May 2016 57th Annual meeting of the Society for Surgery of the Alimentary Tract. Plenary Session. San Diego, CA
52. B George, M Gutierrez, K Kelly, A Ko, HH Soliman, N Trunova, ZA Wainberg, D Waterhouse, P O’Dwyer, H Hochster. Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: preliminary analysis of pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts. Accepted for ESMO 2016, October 7-11, Copenhagen, Denmark
53. Goldman JW, George B, Gutierrez M, Ko A, O’Dwyer PJ, Otterson GA, Soliman HH, Trunova N,. Waterhouse DM, Kelly K .Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer. IASLC 17th World Conference on Lung Cancer, December 4-7, 2016, Vienna, Austria.
54. Jeong SY, Aldakkak M, Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Prognostic Nomogram for Patients with Operable Pancreatic Cancer Treated with Neoadjuvant Therapy. February 2017 12th Annual Academic Surgical Congress. Las Vegas, NV
55. Bahary N, He J, Bailey M, Zhong S, Li G, Young L, Singhi A, Stephens P, Ali SM, Singal G, Betzig Schrock A, Chung J, Ross Jeffery, Miller V, George B. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA). GI ASCO, 2017
56. Blitzer G, Tsai S, Aldakkak M, Hellman R, Evans DB, Christians KK, George B, Ritch PS, Hall WA, Erickson, B. Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer? GI ASCO, 2017
57. Wainberg ZA, Hochster HS, George B, Gutierrez M, Johns ME, Chiorean GE, Kwak EL, Kalyan A, Manax V, Ye M, Chen T, Trunova N, O'Dwyer PJ. Phase I study of nivolumab (nivo) + nab- paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. GI ASCO, 2017
58. George B, Bailey M, Schrock AB, Thorpe L, Gay LM, Ritch PS, Thomas JP, Erickson B, Tsai S, Christians KK, Evans DB, Stephens PJ, Miller VA, Ross JS, Singhi AD, Ali SM. Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC). GI ASCO, 2017
59. Bailey M, Ali SM, Schrock AB, Klempner SJ, George B, Lipson D, He J, Miller VA, Stephens P, Ross JS. Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications. GI ASCO, 2017
60. Wittmann D, Aldakkak M, Rajamanickam EP, Christians KK, Aburajab M, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Impact of Perioperative Changes in CA19-9 Levels in Patients with Resectable and Borderline Resectable Pancreatic Cancer. April 2017 Americas Hepato-Pancreato-Biliary Association Annual Meeting. Miami Beach, FL
61. Jeong SY, Aldakkak M , Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Preoperative Nomogram to Predict Survival for Patients with Resectable and Borderline Resectable Pancreatic Cancer. April 2017 Americas Hepato-Pancreato-Biliary Association Annual Meeting. Miami Beach, FL
62. Barnes C, Aldakkak M, Christians K, Khan A H, Oshima K, Ritch P, George B, Hall W, Erickson B, Evans D, Tsai S. Impact of Nodal Status on Adjuvant Therapy for Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. DDW, 2017
63. Durno C, Aronson M, Edwards M, Ling S, Larouche V, Bronsema A, Osborn M, Stearns D, Cole K, Oren M, Opocher E, Mason G, Thomas G, Sabel M, George B, Ziegler D, Lindhorst S, Magimairajan V, Laperriere N, Samuel D, Bouffet E, Tabori U. Immune Check Point Inhibitor Treatment for Young Patients with Hypermutant Cancers. DDW, 2017
64. Bahary B, He J, Bailey M, Zhong S, Li G, Young L, Singhi A, Stephens P, Mahamad Ali S, Singal G, Schrock A, Chung J, Ross J, Miller V, George B. Genomic Profiling of Circulating Tumor DNA (ctDAN) From Patients (pts) with Pancreatic Ductal Adenocarcinoma (PDA). ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL J Clin Oncol 35, 2017 (suppl; abstr 4128).
65. Chad Barnes, Mohammed Aldakkak, Kathleen K. Christians, Parag Tolat, Paul S. Ritch, Ben George, William Adrian Hall, Beth Erickson, Douglas B. Evans, Susan Tsai. Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery, ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL J Clin Oncol 35, 2017 (suppl; abstr e15766)
66. David Michael Waterhouse, Jonathan Wade Goldman, Ben George, Peter J. O'Dwyer, Moncy Ye, Tianlei Chen, Nataliya Trunova, Karen Kelly. Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study. ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL. J Clin Oncol 35, 2017(suppl; abstr 9095).
67. Barnes CA, Aldakkak M, Christians KK, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase Ii clinical trial of neoadjuvantherapy and surgery. 51st Annual Pancreas Club. 2017 Chicago, IL
68. Wittmann,D, Aldakkak M, Rajamanickam EP, Christians KK, Aburajab M, George B, Ritch PS, Hall WA, Erickson BA, Evans, DB, Tsai S. Impact of perioerative changes in CA19-9 levels in patients with resectable and borderline resectable pancreatic cancer. Poster of Distinction. 51st Annual Pancreas Club. 2017 Chicago, IL
69. Jeong SY, Aldakkak M , Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Preoperative Nomogram to Predict Survival for Patients with Resectable and Borderline Resectable Pancreatic Cancer. 51st Annual Pancreas Club. 2017 Chicago, IL
70. Singavi AK, Menon S, Kilari D, Alqwasmi AH, Thomas JP, Ritch PS, Martin A, Oxencis C, Ali SM, George B. Predictive biomarkers for Hyper-progression (HP) in response to Immune Checkpoint Inhibitors (ICI) – Analysis of Somatic Alterations(SAs). ESMO 2017 Congress, September 8-12, Madrid, Spain (Merit award for Singavi AK).
71. Narra RK, Singavi AK, Ritch PS, Thomas JP, Alqwasmi AH, George B. Therapeutic relevance of homologous recombination repair (HRR) pathway variants in metastatic colorectal cancer. GI ASCO 2018, January 18-20, San Francisco, CA.
72. Singavi AK, Szabo A, Thomas JP, Ritch PS, Alqwasmi AH, White S, Rilling WS, George B. Costs of Care with Liver Directed Therapy (LDT) and Sorafenib (S) in Patients with Advanced Hepatocellular Carcinoma (HCC). GI ASCO 2018, January 18-20, San Francisco, CA.
73. George B, Greenbowe J, Hendifar AE, Golan T, Javle MM, Maitra A, Bahary N, Yakirevich E, Ritch PS, Thomas JP, Schrock AB, Miller VA, Stephens PJ, Ross JS, Ali SM, Singhi A. Comprehensive Genomic Profiling (CGP) in KRAS Wild-Type (WT) Pancreatic Ductal Adenocarcinoma (PDAC). GI ASCO 2018, January 18-20, San Francisco, CA.
74. Aatur D. Singhi, Joel R. Greenbowe, Jon Chung, Andrew Eugene Hendifar, Nathan Bahary, Alexa Betzig Schrock, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Siraj Mahamed Ali, Ben George. Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma. GI ASCO 2018, January 18-20, San Francisco, CA
75. Narra KR, Singavi A, Thompson J, Menon S, Oxencis, C, Riese M, Thomas JP, Ritch P, Kilari D, Szabo A, George, B. Application of comprehensive genomic profiling (CGP) to predict therapeutic response to immune checkpoint Inhibitors (ICI). AACR 2018, April 14-18, Chicago, IL.
76. Tsai S, Christians K, George B, Paul R, Dua K, Khan A, Mackinnon AC. Tolat P, Hall W, Erickson B, Evans D; A Prospective Clinical Trial of Personalized Medicine for Operable Pancreatic Cancer. American Surgical Association, 138th Annual Meeting, April 19-20, 2018, Phoenix, AZ.
77. Wong M, Kim J, Robbins J, George B, Zimmerman M, Hong J; Outcomes Analysis of Liver Transplantation Combined with Neoadjuvant Therapy in Patients with Unresectable Locally-Advanced Cholangiocarcinoma. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
78. Barnes C, Aldakkak M, Clarke C, Christians K, Aburajab M, George B, Ritch P, Hall W, Erickson B, Evans D, Tsai S; Operative Management of Locally Advanced Pancreatic Cancer: Analysis of the National Cancer Database. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
79. Barnes C, Cho Y, Aldakkak M, Clarke C, Christians K, Khan A, George B, Ritch P, Hall W, Erickson B, Evans D, Tsai S; Conditional Survival for Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy and Surgery – A Single Institution Experience. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI
80. Stein A, George B, Thomas J, Tsai S, Clarke C, Gamblin T, Mogal H; Molecular and Genetic Markers in Appendiceal Mucinous Neoplasms – A Systematic Review. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
81. Kelm S, Longo J, Bedi M, Siker, M, Thomas J, George B, Ludwig K, Peterson C, Ridolfi T, Erickson B; The Impact of Hemoglobin on Outcomes in Anal Canal Cancer Treated with Definitive Chemoradiation. ASTRO Annual Meeting, October 21, 2018, San Antonio, TX
82. Johnson M, Patel M, Ulahannan S, Hansen A, George B, Chu Q, Elgadi M, Ge M, Duffy C, Graeser R, Khedkar, Jones S, Burris H; Phase 1 Study of BI 754111 (anti-LAG-3) plus BI 754091 (anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L) 1-pretreated non-small-cell lunch cancer (NSCLC) and other solid tumors. 2018 ESMO Congress, October 19-23 2018, Munich, Germany
83. Ilson DH, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience PC, Beretta GD, Masoor W, Zhavrid E, Alsina M, George B, Catenacci D, Winkler R, Makris L, Doi R, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy; Results from a phase III study (TAGS) Oral Presentation. GI ASCO January 17, 2019
84. Wainberg ZA, Hochster HS, Kim EJH, George B, Kalyan A, Chiorean GE, Waterhouse DM, Gutierrez M, Parikh AR, Jain R, Carrizosa DR, Hussein S, Bhore R, Banerjee S, Lyons L, Louis CU, Jin Ong P, O’Dwyer PJ. Phase I study of nivolumab (nivo) + nab- paclitaxel (nab-P) ± gemcitabine (Gem) in advanced pancreatic cancer. GI ASCO, 2019
85. Van Cutsem E, Hochster H, Kohei S, Mayer R, Ohtsu A, Falcone A, Yoshino T, Doi T, Ilsond, Arkenau T, George B, McGuigan S, Makris L, Tabernero J Pooled Safety Analysis From Phase 3 Studies of Trifluridine/tipiracil (FTD/TPI) in Patients (pts) with Metastatic Gastric/Gastroesophageal Junction Cancer (mGC/mGEJC) and Metastatic Colorectal Cancer (cCRC). ASCO Annual Meeting, 2019 May 31-June 4, Chicago, IL
86. Sohal D, Doudement J, George B, Alexander B, Grant SC, Kim WY, Gutierrez ME, Kelly KW, Knudsen KE, McPherson JD, Hoimes C, Davis EJ, Singal G, Webster J, Chan L, Cristofanilli M, Miller VA. Accelerating Advanced Precision Medicine Through a Harmonized Data Exchange Platform and Research Consortium (PMEC). ASCO Annual Meeting, 2019 May 31-June 4, Chicago, IL
87. Lau J, Teichgraeber V, Lopez C, Allen S, Barak H, Kim Kyu-pyo, Chung V, Ci B, George B, Oh Do-Youn, Kindler H, Zhang X, Shemesh C, Alistar A, Retiere A-C. Phase Ib/II, open-label, randomized evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma (PDAC). ESMO GI, Spain September 18-22, 2020
88. Peter Thuss-Patience, Sylvie Lorenzen, Thomas Ettrich, Meinolf Karthaus, David H. Ilson, Aliaksandr Prokharau, Tobias Arkenau, Michele Ghidini, Kazumasa Fujitani, Eric Van Cutsem, Giordano D. Beretta, Wasat Mansoor, Edvard Zhavrid, Maria Alsina, Ben George, Daniel Catenacci, Lukas Makris, Toshihiko Doi, and Kohei Shitara. Wirksamkeitund Sicherheit von Trifluridin/Tipiracil (FTD/TPI) bei Patientinnen und Patienten mit metastasiertem Magenkarzinom (mGC) mit oder ohne vorherige Gastrektomie: Ergebnisse einer Phase-III-Studie (TAGS). Encore presentation. Annual DGHO Meeting, Berlin, Germany October 11-15, 2019
89. Bendell J, Ulahannan S, Chu Q, Patel M, George B, Elgadi M, Duffy C, Graeser R, Tang W, Merger M, Ge M, Johnson M. A Phase I, dose finding study of BI 754111, an anit-LAG-3 antibody, in combination with BI 754091, and anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable metastatic colorectal cancer cohort. AACR-NCI-EORTC October 26-30, 2019
90. Menon S, Ellis C, Poudel S, Johnson J, Szabo A, George B, Kelly K, Grant S, McPherson J, Davis E, Cristofanilli M, Hoimes C, Gutierrez M, Doudement J, Chan L, Singal G, Alexander B, Miller V, Sohal D. Impact of STK11 and c-MYC alterations in metastatic NSCLC. AACR/IASLC Meeting San Diego, CA, Jan 11-14, 2020
91. George B, Van Cutsem E, Hochster H, Mayer R, Ohtsu A, Falcone A, Yoshino T, Doi T, Ilson D, Arkenau H-T, Benhadji K A, Makris L, Tabernero J, Shitara K Analysis of hematologic adverse events in trifluridine/tipiracil (FTD/TPI)-treated patients with or without renal/hepatic impairment: Pooled safety analyses from TAGS and RECOURSE. GI ASCO, San Francisco, CA January 23-25, 2020
92. Chiorean EG, Ritch P, Zhen D B, Poplin E, George B, Hendifar A E, Dragovich T, Coveler A L, Stoll-D'Astice A, Edwards S, Rosenthal A, Thorsen SM, Hingorani SR. PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA). GI ASCO, San Francisco, CA January 23-25, 2020
93. Annunzio, K, Griffiths, C, Arapi, I, Lasowsksi, M, Singavi, A, Dua, K, Khan A, Ritch P, Kamgar M, Thomas JP, Hall, W, Erickson B, Tsai S, Christians KK, Evans DB, Raul Urrutia, Szabo, A, George, B. CDKN2A/B status has predictive impact in Pancreatic Cancer (PC). GI ASCO, San Francisco, CA January 23-25, 2020
94. Lasowski, M, Stachowiak, S, Arapi, I, Dua, K, Khan, A, Hall, W, Erickson, B, Tsai, S, Christians, KK, Evans, DB, Ritch, P, Kamgar, M, Thomas, JP, Raul Urrutia, George, B. Utilization of Somatic Comprehensive Genomic Profiling (CGP) to identify patients (pts) with Pancreatic Cancer (PC) that harbor germ line DNA Damage Repair (DDR) gene alterations GI ASCO, San Francisco, CA January 23-25, 2020
95. Bendell J, Ulahannan SV, Chu Q, Patel M, George B, Auguste A, Leo-Kress T, Bernd Stadermann K, Kraemer N, Elgadi M, Johnson M. A Phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort. AACR 2020, San Diego, CA April 20-24, 2020
96. George B, Richards D, Edenfield WJ, Warner S, Mouritsen L, Bishop R, Anthony S, Bearss S, Vogelzang N, Whatcott C, FH/MCW, US Oncology Research, Tyler, TX: Institute for Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; Tolero Pharmaceuticals, Inc., Lehi, UT; Tolero Pharmaceuticals, Inc, Lehi, UT; Comprehensive Cancer Centers of Nevada, Las Vegas, NV A phase I, first-in-human, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP 1287 administered daily to patients with advanced solid tumors.ASCO Annual Meeting, Chicago, IL May 29-June 2, 2020
97. George B, Taylor B, Lasowski M, Ritch P, Shreenivas A, Chakrabarti S, Kamgar M, Zimmermann M, Reddi H, Urrutia R, Thomas JP, A phase I, first-in-human, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP 1287 administered daily to patients with advanced solid tumors.Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC). ASCO Annual Meeting, Chicago, IL May 29-June 2, 2020
98. Shreenivas A, Guru Murthy GU, George B, Thomas JP, Chakrabarti S, Kamgar M, Ritch P, Medical College of Wisconsin, Froedtert & The Medical College of Wisconsin, Milwaukee, WI; Mayo Clinic, Rochester, MN.Impact of tumor histology and socioeconomic factors on survival of patients suffering from malignant vascular tumors of liver and hepatocellular carcinomas: A SEER database analysis. ASCO Annual Meeting. May 29-June 2, 2020
99. Johnson M, Patel M, Cherry M, Kang Y-K, Yamaguchi K, Oh D-Y, Hussein M, Kitano S, Kondo S, Hansen AR, Percent IJ, George B, Arrowsmith E, Morimoto M, Duffy C, Ge M, Rohrbacher M, Elgadi M, Bendell J. Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors ASCO Annual Meeting. May 29-June 2, 2020
100. Chung V, Alistar A, George B,Kim K-P, Kindler H, Oh D-Y, Allen S, Barak H, Ci B, Lau J, Retiere A-C, Shemesh C, Teichgräber V, Zhang X, Lopez C. Phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma (PDAC). ESMO GI Congress, July 1-4, 2020